Su1346 ANTICOAGULATION STATUS AND REBLEEDING FOLLOWING DOUBLE BALLOON ENTEROSCOPY FOR OBSCURE GI BLEEDING

Spencer, Chad; Nunley, Benjamin; Baldwin, Nicholas; Redden, David; Peter, Shajan

doi:10.1016/j.gie.2019.03.473

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bhattacharya et al found 0 patients in their 1447 patient cohort that had intraoperative or delayed (30 days) rebleeding post DBE 8 . Spencer et al with a total cohort of 86 patients reported a rebleeding rate post-DBE was 5.8 % in patients at 30 days and 12.8 % at 60 days 9 . Both studies reported no statistically significant association between AP/AC use and post-DBE rebleeding.…”

Section: Discussionmentioning

confidence: 96%

“…On antiplatelet therapy (N = 183) Not on antiplatelet therapy (N = 457) P value [9]. Both studies reported no statistically significant association between AP/AC use and post-DBE rebleeding.…”

Section: Enteroscopy Characteristicsmentioning

confidence: 91%

“…Current American Society for Gastrointestinal Endoscopy guidelines recommend holding antiplatelet (AP)/anticoagulant (AC) therapy in high-risk bleeding procedures including therapeutic DBE 7 . However, continuation of AP/AC therapy could, theoretically, provoke bleeding during DBE, facilitating the identification of the source, especially in patients who present with obscure gastrointestinal bleeding, the most common indication for DBE 8 9 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of bleeding following double balloon enteroscopy in patients on continued antiplatelet and/or anticoagulation therapy

et al. 2021

View full text Add to dashboard Cite

Background and study aims Anticoagulation (AC) and antiplatelet (AP) therapy may increase the risk of gastrointestinal bleeding after double balloon enteroscopy (DBE); however, limited data are currently available regarding the incidence. The aim of this study was to assess the incidence and clinical characteristics of post-DBE bleeding in patients on AC and AP therapy. Patients and methods The medical records of patients who underwent DBE between 2009 and 2013 at Mayo Clinic, Florida, were retrospectively reviewed. Patients were divided into three groups: 1) continued AP therapy; 2) AC therapy; and 3) neither AP nor AC at the time of DBE. Follow-up data were collected at 60 days and 1 year. Results A total of 683 patients were identified; 43 on AC, 183 on AP and 457 not on AP or AC therapy. The most common indication for DBE was obscure gastrointestinal bleeding in the groups on and not on AP (85.3 % vs 70.9 %, P < 0.0001). There was no statistical difference in post-DBE bleeding rates in patients on AP vs not on AP at 60 days (11.5 % vs 7.5 %, P = 0.12) or 1 year (19.9 % vs 15.7 %, P = 0.23). Rates of bleeding in patients on AC were 11.6 % within 60 days and 22.5 % within 1 year. Multivariate analysis reflected American Society of Anesthesiologist > 3 and indication for DBE of GI bleeding were independent risk factors for post-DBE bleeding within 1 year. Conclusions Continued antiplatelet use at the time of DBE was not an independent risk factor for bleeding post-DBE at 60 days or 1 year of follow up.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Enteroscopy Characteristicsmentioning

confidence: 91%